Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "neuropathy"

18 News Found

Medtronic gets USFDA approval of spinal cord stimulation therapy
Medical Device | January 25, 2022

Medtronic gets USFDA approval of spinal cord stimulation therapy

Studies show significant reduction in pain and improved quality of life for patients treated with spinal cord stimulation compared to medication management alone


Eplontersen granted Orphan Drug Designation in the US
Biotech | January 24, 2022

Eplontersen granted Orphan Drug Designation in the US

The FDA grants ODD status to medicines and potential new medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US


Alkem Labs to launch treatment for Diabetic Foot Ulcer
News | January 12, 2022

Alkem Labs to launch treatment for Diabetic Foot Ulcer

This advanced technology for Diabetic Foot Ulcer (DFU), management has a high scope of preventing amputations in diabetic patients. It has no definitive treatment in India. This technology will be available at affordable rates


Cadila Pharma launches ayurvedic energy tonic Healtherbs
Healthcare | December 08, 2021

Cadila Pharma launches ayurvedic energy tonic Healtherbs

Healtherbs helps in restoring the desired energy levels for daily activity and immunity


Aster Volunteers offer free diabetes screening in India and UAE
Events | December 03, 2021

Aster Volunteers offer free diabetes screening in India and UAE

In 2019, diabetes was the ninth leading cause of death with an estimated 1.5 million deaths directly caused by diabetes, as per WHO


Lupin launches Droxidopa capsules in the US
Drug Approval | September 29, 2021

Lupin launches Droxidopa capsules in the US

Droxidopa capsules, 100 mg, 200 mg, and 300 mg is a generic equivalent of Northera capsules, 100 mg, 200 mg, and 300 mg, of Lundbeck NA


Lupin receives approval for Droxidopa capsules
News | February 20, 2021

Lupin receives approval for Droxidopa capsules

Droxidopa Capsules, 100 mg, 200 mg, and 300 mg, are indicated for the treatment of orthostatic dizziness


WACKER acquires plasmid DNA Manufacturer Genopis
News | February 05, 2021

WACKER acquires plasmid DNA Manufacturer Genopis

WACKER and Helixmith plan to strategically collaborate on the production of a pDNA gene therapy developed by Helixmith for the treatment of diabetic peripheral neuropathy (DPN).